PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today posted an overview of new data on daclatasvir (or BMS-790052) on the company website. Daclatasvir is an NS5A replication complex inhibitor in Phase III development for the treatment of hepatitis C. These data were presented Thursday, March 8, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb CompanyMedia:Cristi L. Barnett, 609-252-6028cristi.barnett@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com